Jul 14 2020
The ongoing COVID-19 pandemic has presented an urgent need for new therapeutic options for the treatment, alleviation and prevention of this disease. Due to the length of time it takes to bring a new molecule to the market, redeploying existing drugs to address the disease has become a heavily favoured approach; successes have been achieved with dexamethasone and remdesivir.
Repurposing of pharmaceuticals in this way presents unique intellectual property challenges. A pre-existing patent landscape exists almost by definition, which must be dealt with. Obtaining valuable patent protection for the new use is challenging, with the rules varying from country to country. Finally, enforcement of rights needs a nuanced approach.
Expert speakers from three jurisdictions will address these issues, with an emphasis on practical steps that organisations can take to develop a coherent IP strategy for repurposing a known drug.
Date: Thursday, July 30
Time: 12:00-1:00 PM EST
Sophie Maughan (United Kingdom) – partner, Cleveland Scott York LLP
Charles Boulakia (Canada) is a partner of Ridout & Maybee LLP in the firm’s Toronto office. His practice is principally directed towards the preparation and prosecution of patent applications in the biotechnology and pharmaceutical areas.
Kelly Echols (United States) is a partner of Stoel Rives LLP in Salt Lake City. He has counseled pharmaceutical, medical device, diagnostic, and chemical companies. He previously acted as Director of Contracts and Patent Counsel for Myrexis, Inc.
Adrian Bradley (United Kingdom) is a partner of Cleveland Scott York LLP and a European and UK patent attorney. He specialises in the pharmaceutical and healthcare sector, having acted as in-house counsel for Wyeth Pharmaceuticals (now Pfizer).
Back to blog overview
Tags: Charles Boulakia, Events, Firm News, Webinar